skip to main content
Idioma:
Primo Search
Clear Search Box
Search in: Busca Geral
Busca Avançada
Busca por Índices

Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies

Banach, Maciej ; Penson, Peter E.

Current atherosclerosis reports, 2021-07, Vol.23 (7), p.32-32, Article 32 [Periódico revisado por pares]

New York: Springer US

Texto completo disponível

Citações Citado por
  • Título:
    Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies
  • Autor: Banach, Maciej ; Penson, Peter E.
  • Assuntos: Angiology ; Cardiology ; Coronary Heart Disease (S. Virani and S. Naderi ; Coronary Heart Disease (S. Virani and S. Naderi, Section Editors) ; Medicine ; Medicine & Public Health ; Section Editors ; Topical Collection on Coronary Heart Disease
  • É parte de: Current atherosclerosis reports, 2021-07, Vol.23 (7), p.32-32, Article 32
  • Notas: ObjectType-Article-2
    SourceType-Scholarly Journals-1
    ObjectType-Feature-3
    content type line 23
    ObjectType-Review-1
  • Descrição: Purpose of Review Recent studies have demonstrated an important role for inflammation in the pathogenesis of atherosclerotic cardiovascular disease. Several studies have investigated the efficacy of colchicine (a widely used and safe anti-inflammatory drug) in patients with atherosclerosis. This review explains the rationale for the use of colchicine in this setting and critically appraises recent outcome trials. Recent Findings Two large randomised-controlled trials LoDoCo2 (included patients with chronic coronary syndromes) and COLCOT (acute coronary syndromes) have demonstrated reductions in atherosclerotic cardiovascular events, but not mortality. A smaller study (COPS) found no beneficial effect of colchicine but was probably underpowered. Summary Colchicine is effective at reducing cardiovascular events in chronic and acute coronary syndromes, although reductions in all-cause mortality have not been demonstrated during the period of follow-up in trials to date. Mild gastrointestinal symptoms are the most commonly reported adverse effects, although in well-designed randomised controlled trials these are relatively uncommon.
  • Editor: New York: Springer US
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.